In this video from Tuesday's Market Checkup, Motley Fool health care analyst David Williamson takes investors through the biggest investing stories in the health care space today.

Shares of Hansen Medical (NASDAQ:HNSN) shot up 20% today, on news that the company received FDA approval for a new robotic catheter, the Magellan 6Fr. Hansen also named Chris Lowe as its new CEO, to replace outgoing Bruce Barclay. While investors are hoping that approval of the Magellan 6Fr will keep the momentum going for the robotic catheter maker, sales were very light for Hansen in 2013. Q1 2013 sales came in at $2 million, increasing to more than $5 million last quarter, but David sees the company as needing to do much more to justify its valuation. With its current cash burn rate and relatively low cash position, investors could be risking exposure to a dilutive event here.

Medical technology is changing rapidly. How can investors play this volatile space?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.